EVI1 is critical for the pathogenesis of a subset of MLL-AF9-rearranged AMLs

Blood

Volumn 119, Issue 24, 2012, Pages 5838-5849

  Bindels, Eric M J ^a   Havermans, Marije ^a   Lugthart, Sanne ^a   Erpelinck, Claudia ^a   Wocjtowicz, Elizabeth ^b   Krivtsov, Andrei V ^c,d   Rombouts, Elwin ^a   Armstrong, Scott A ^c,d   Taskesen, Erdogan ^a   Haanstra, Jurgen R ^a   Beverloo, H Berna ^a   Döhner, Hartmut ^e   Hudson, Wendy A ^f   Kersey, John H ^f   Delwel, Ruud ^a   Kumar, Ashish R ^b,f  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF ULM   (Germany)

^f UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MIXED LINEAGE LEUKEMIA PROTEIN; SHORT HAIRPIN RNA;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL MODEL; APOPTOSIS; ARTICLE; BONE MARROW CELL; CANCER INHIBITION; CELL CYCLE; CELL TRANSFORMATION; COHORT ANALYSIS; COLONY FORMING UNIT GM; CONTROLLED STUDY; ECOTROPIC VIRAL INTEGRATION SITE 1; FUSION GENE; GENE EXPRESSION; GENE TRANSLOCATION; IMMUNOPHENOTYPING; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO CULTURE; MOLECULAR DYNAMICS; MORPHOLOGY; MOUSE; NONHUMAN; ONCOGENE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 84862497497     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-11-393827     Document Type: Article

References (49)

1. Bullinger L, Döhner K, Bair E, et al. Use of geneexpression profiling to identify subclasses in adult acute myeloid leukemia. N Engl J Med. 2004;350(16):1605-1616.
2. Valk PJ, Verhaak RG, Beijen MA, et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med. 2004;350(16):1617-1628. (Pubitemid 38528701)
3. Figueroa ME, Lugthart S, Li Y, et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell. 2010;17(1):13-27.
4. Morishita K, Parker DS, Mucenski ML, et al. Retroviral activation of a novel gene encoding a zinc finger protein in IL-3-dependent myeloid leukemia cell lines. Cell. 1988;54(6):831-840.
5. Delwel R, Funabiki T, Kreider BL, et al. Four of the seven zinc fingers of the Evi-1 myeloid-transforming gene are required for sequencespecific binding to GA(C/T)AAGA(T/C)AAGATAA. Mol Cell Biol. 1993;13(7):4291-4300. (Pubitemid 23187658)
6. Perkins AS, Fishel R, Jenkins NA, et al. Evi-1, a murine zinc finger proto-oncogene, encodes a sequence-specific DNA-binding protein. Mol Cell Biol. 1991;11(5):2665-2674. (Pubitemid 21895646)
7. Izutsu K, Kurokawa M, Imai Y, et al. The corepressor CtBP interacts with Evi-1 to repress transforming growth factor beta signaling. Blood. 2001;97(9):2815-2822.
8. Chakraborty S, Senyuk V, Sitailo S, et al. Interaction of EVI1 with cAMP-responsive element-binding protein-binding protein (CBP) and p300/CBP-associated factor (P/CAF) results in reversible acetylation of EVI1 and in colocalization in nuclear speckles. J Biol Chem. 2001;276(48):44936-44943.
9. Vinatzer U, Taplick J, Seiser C, et al. The leukaemia-associated transcription factors EVI-1 and MDS1/EVI1 repress transcription and interact with histone deacetylase. Br J Haematol. 2001;114(3):566-573. (Pubitemid 32953634)
10. Lugthart S, Figueroa ME, Bindels E, et al. Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1. Blood. 2010;117(1):234-241.
11. Senyuk V, Premanand K, Xu P, et al. The oncoprotein EVI1 and the DNA methyltransferase Dnmt3 co-operate in binding and de novo methylation of target DNA. PLoS One. 2011;6:e20793.
12. Spensberger D, Vermeulen M, Le Guezennec X, et al. Myeloid transforming protein EVI1 interacts with methyl-CpG binding domain protein 3 and inhibits in vitro histone deacetylation by Mbd3/ Mi-2/NuRD. Biochemistry. 2008;47(24):6418-6426. (Pubitemid 351874233)
13. Goyama S, Nitta E, Yoshino T, et al. EVI-1 interacts with histone methyltransferases SUV39H1 and G9a for transcriptional repression and bone marrow immortalization. Leukemia. 2010;24(1):81-88.
14. Buonamici S, Li D, Chi Y, et al. EVI1 induces myelodysplastic syndrome in mice. J Clin Invest. 2004;114(5):713-719. (Pubitemid 39582822)
15. Konrad TA, Karger A, Hackl H, et al. Inducible expression of EVI1 in human myeloid cells causes phenotypes consistent with its role in myelodysplastic syndromes. J Leukocyte Biol. 2009;86(4):813-822.
16. Yuasa H, Oike Y, Iwama A, et al. Oncogenic transcription factor EVI1 regulates hematopoietic stem cell proliferation through GATA-2 expression. EMBO J. 2005;24(11):1976-1987. (Pubitemid 40896169)
17. Laricchia-Robbio L, Nucifora G. Significant increase of self-renewal in hematopoietic cells after forced expression of EVI1. Blood Cells Mol Dis. 2008;40(2):141-147. (Pubitemid 351221372)
18. Haas K, Kundi M, Sperr WR, et al. Expression and prognostic significance of different mRNA 5′-end variants of the oncogene EVI1 in 266 patients with de novo AML: EVI1 and MDS1/EVI1 overexpression both predict short remission duration. Genes Chromosomes Cancer. 2008;47(4):288-298. (Pubitemid 351323758)
19. Lugthart S, van Drunen E, van Norden Y, et al. High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated. Blood. 2008;111(8):4329-4337.
20. Gröschel S, Lugthart S, Schlenk RF, et al. High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities. J Clin Oncol. 2010;28(12):2101-2107.
21. Russell M, List A, Greenberg P, et al. Expression of EVI1 in myelodysplastic syndromes and other hematologic malignancies without 3q26 translocations. Blood. 1994;84(4):1243-1248.
22. Balgobind BV, Lugthart S, Hollink IH, et al. EVI1 overexpression in distinct subtypes of pediatric acute myeloid leukemia. Leukemia. 2010;24(5):942-949.
23. Chen W, Kumar AR, Hudson WA, et al. Malignant transformation initiated by Mll-AF9: gene dosage and critical target cells. Cancer Cell. 2008;13(5):432-440. (Pubitemid 351609442)
24. Goyama S, Yamamoto G, Shimabe M, et al. Evi-1 is a critical regulator for hematopoietic stem cells and transformed leukemic cells. Cell Stem Cell. 2008;3(2):207-220.
25. Arai S, Yoshimi A, Shimabe M, et al. Evi-1 is a transcriptional target of mixed-lineage leukemia oncoproteins in hematopoietic stem cells. Blood. 2011;117(23):6304-6314.
26. Balgobind BV, Zwaan CM, Reinhardt D, et al. High Bre expression in pediatric MLL-rearranged AML is associated with favorable outcome. Leukemia. 2010;24(5):2048-2055.
27. Jansen MWJC, van der Velden VHJ, van Dongen JJM. Efficient and easy detection of MLL-AF4, MLL-AF9 and MLL-ENL fusion gene transcripts by multiplex real-time quantitative RT-PCR in TaqMan and LightCycler. Leukemia. 2005;19(11):2016-2018. (Pubitemid 41554019)
28. Shaffer LG, Tommerup N, eds. ISCN 2005: An International System for Human Cytogenetic Nomenclature. Basel, Switzerland: S. Karger; 2005.
29. Kumar AR, Li Q, Hudson WA, et al. A role for MEIS1 in MLL-fusion gene leukemia. Blood. 2009;113(8):1756-1758.
30. Pieters R, den Boer ML, Durian, et al. Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia-implications for treatment of infants. Leukemia. 1998;12(9):1344-1348. (Pubitemid 28442379)
31. Verhaak RG, Wouters BJ, Erpelinck CA, et al. Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling. Haematologica. 2009;94(1):131-134.
32. Meyer C, Kowarz E, Hofmann J, et al. New insights to the MLL recombinome of acute leukemias. Leukemia. 2009;23(8):1490-1499.
33. Krivtsov AV, Armstrong SA. MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer. 2007;7(11):823-833. (Pubitemid 350006257)
34. Gröschel S, Richard FS, Engelmann J, et al. Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian AMLSG and Dutch-Belgian HOVON groups. J Clin Oncol. 2012; In press.
35. Krivtsov AV, Feng Z, Lemieux ME, et al. H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell. 2008;14(15): 355-368.
36. Thiel AT, Blessington P, Zou T, et al. MLL-AF9- induced leukemogenesis requires coexpression of the wild-type Mll allele. Cancer Cell. 2010; 17(2):148-159.
37. Cozzio A, Passegué E, Ayton PM, et al. Similar MLL-associated leukemias arising from selfrenewing stem cells and short-lived myeloid progenitors. Genes Dev. 2003;17(24):3029-3035.
38. Eppert K, Takenaka K, Lechman ER, et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med. 2011; 17(9):1086-1093.
39. Noordermeer SM, Sanders MA, Gilissen C, et al. High BRE expression predicts favorable outcome in adult acute myeloid leukemia, in particular among MLL-AF9-positive patients. Blood. 2011; 118(20):5613-5621.
40. Du Y, Jenkins NA, Copeland NG. Insertional mutagenesis identifies genes that promote the immortalization of primary bone marrow progenitor cells. Blood. 2005;106(12):3932-3939. (Pubitemid 41739034)
41. Bernt KM, Zhu N, Sinha AU, et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell. 2011;20(1):66-78.
42. Tan J, Muntean AG, Hess JL. PAFc, a key player in MLL-rearranged leukemogenesis. Oncotarget. 2010;1(6):461-465.
43. Smith E, Lin C, Shliatifard A. The super elongation complex and MLL in development and disease. Genes Dev. 2011;25(7):661-672.
44. Milne TA, Kim J, Wang GG, et al. Multiple interactions recruit MLL1 and MLL1 fusion proteins to the HOXA9 locus in leukemogenesis. Mol Cell. 2010;38(6):853-863.
45. Bitoun E, Oliver PL, Davies KE. The mixed-lineage leukemia fusion partner AF4 stimulates RNA polymerase II transcriptional elongation and mediates coordinated chromatin remodeling. Hum Mol Genet. 2007;16(1):92-106. (Pubitemid 46152547)
46. Mueller D, Bach C, Zeisig D, et al. A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification. Blood. 2007; 110(13):4445-4454. (Pubitemid 351377811)
47. Muntean AG, Tan J, Sitwala K, et al. The PAF complex synergizes with MLL fusion proteins at HOX loci to promote leukemogenesis. Cancer Cell. 2010;17(6):609-621.
48. Daigle SR, Olhava EJ, Therkelsen CA, et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell. 2011;20(1):53-65.
49. Dawson MA, Prinjha RK, Dittman A, et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukemia. Nature. 2011;478(7370):529-533.